Literature DB >> 7513109

Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor.

S R Prahalada1, K P Keenan, P R Hertzog, L R Gordon, C P Peter, K A Soper, M J van Zwieten, D L Bokelman.   

Abstract

OBJECTIVE: To determine any potential direct and/or indirect effects of elevated intraprostatic T levels on the prostates of rats chronically (1-2 years) exposed to high doses (160 mg/kg/day) of finasteride, a selective inhibitor of 5-alpha reductase.
METHODS: Sprague-Dawley male rats were administered daily finasteride by oral gavage. Prostates from all rats were weighed, fixed in 10% neutral buffered formalin, and processed for light microscopic examination. The volume fractions of the prostatic glandular and stromal compartments were quantitated by morphometric analysis.
RESULTS: Administration of finasteride at doses of 20, 40, and 80 mg/kg/day for one year resulted in a significant (P < or = 0.05) decrease in prostatic weight; prostatic atrophy was evident by light microscopy. Morphometric analysis of the prostate showed that chronic finasteride administration resulted in a significant (P < or = 0.001) decrease in the absolute volume of both glandular (-65.2%) and stromal (-57.1%) compartments of the prostate. Furthermore, the total number of epithelial and stromal cells per gland were significantly (P < or = 0.002) decreased in finasteride-treated rats compared with vehicle controls; the magnitude of mean decrease was 69.8 percent and 50.6 percent of controls in epithelial and stromal cells, respectively. In addition, prostates from all two hundred fifty rats in a two-year study were qualitatively evaluated by light microscopy. Administration of finasteride at doses ranging from 2.5 mg/kg/day to 160 mg/kg/day for two years did not result in an increase over the background incidence of prostatic focal hyperplasia or adenoma. No malignant tumors of the prostate were seen in any of the groups.
CONCLUSIONS: These studies have demonstrated that the expected pharmacologic effects of finasteride on the prostate are maintained following chronic treatment and that there was no evidence of a direct and/or an indirect effect of elevated intraprostatic T on prostatic morphology in rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513109     DOI: 10.1016/0090-4295(94)90184-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.

Authors:  R Montironi; M Valli; G Fabris
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

2.  Prostate pathology case study seminar.

Authors:  R Montironi; E Alexander; D G Bostwick
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 3.  Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.

Authors:  A Kirschenbaum; E Pacheco; B J Schuval; A C Levine
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate.

Authors:  A Erdem Canda; M Ugur Mungan; Osman Yilmaz; Kutsal Yorukoglu; Emre Tuzel; Ziya Kirkali
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

6.  Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation.

Authors:  Tarek A Ahmed
Journal:  Int J Nanomedicine       Date:  2016-02-02

7.  Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation.

Authors:  Tarek A Ahmed; Ahmed M Al-Abd
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.